| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a59e1f95aade2c84da43e1fecc6632d5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-06001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 |
| filingDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b1cd32daf839df7264a51ccd8d6c989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8078a1ee3b3571e21ba837e8ab3fa02c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a9edfdbb8ef0b9dec1b69a77051379e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f70d0b27d51dc673b65aa9a96cef3efe |
| publicationDate |
2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019093171-A1 |
| titleOfInvention |
Mutant genes related to drug resistance and relapse of acute lymphoblastic leukaemia and a use thereof |
| abstract |
This disclosure provides mutant genes related to drug resistance and relapse of acute lymphoblastic leukaemia (ALL) and a use thereof, treatment or prevention of drug resistance and relapse of ALL and a use thereof, a use of compound Lometrexol and related inhibitors targeting GART and AITC in prevention and treatment of drug resistance and relapse of ALL, and a kit for evaluation of the risk of drug resistance and relapse of ALL. The mutation gene is a mutant gene of PRPS1. The drug acts on enzymes in purine synthesis pathway and reduces drug resistance and relapse by decreasing the concentration of hypoxanthine. The kit comprises reagents for lysis of sample cells and an instruction, wherein the instruction comprises: (i) collection and lysis of the sample cells; (b) determination of the contents of hypoxanthine, IMP, AICAR and Inosine; (c) evaluation of the risk of the drug resistance and relapse of ALL. The invention provides a powerful technical means and support for the prevention and treatment of drug resistance and relapse of ALL. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022192193-A1 |
| priorityDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |